Therapeutic potential of cannabinoids in the treatment of neuroinflammation associated with Parkinson's disease
Research output: Contribution to journal › Review › Research › peer-review
Standard
Therapeutic potential of cannabinoids in the treatment of neuroinflammation associated with Parkinson's disease. / Little, J P; Villanueva, Erika B; Klegeris, A.
In: Mini reviews in medicinal chemistry, Vol. 11, No. 7, 06.2011, p. 582-90.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Therapeutic potential of cannabinoids in the treatment of neuroinflammation associated with Parkinson's disease
AU - Little, J P
AU - Villanueva, Erika B
AU - Klegeris, A
PY - 2011/6
Y1 - 2011/6
N2 - The cannabinoid system is represented by two principal receptor subtypes, termed CB1 and CB2, along with several endogenous ligands. In the central nervous system it is involved in several processes. CB1 receptors are mainly expressed by neurons and their activation is primarily implicated in psychotropic and motor effects of cannabinoids. CB2 receptors are expressed by glial cells and are thought to participate in regulation of neuroimmune reactions. This review aims to highlight several reported properties of cannabinoids that could be used to inhibit the adverse neuroinflammatory processes contributing to Parkinson's disease and possibly other neurodegenerative disorders. These include anti-oxidant properties of phytocannabinoids and synthetic cannabinoids as well as hypothermic and antipyretic effects. However, cannabinoids may also trigger signaling cascades leading to impaired mitochondrial enzyme activity, reduced mitochondrial biogenesis, and increased oxidative stress, all of which could contribute to neurotoxicity. Therefore, further pharmacological studies are needed to allow rational design of new cannabinoid-based drugs lacking detrimental in vivo effects.
AB - The cannabinoid system is represented by two principal receptor subtypes, termed CB1 and CB2, along with several endogenous ligands. In the central nervous system it is involved in several processes. CB1 receptors are mainly expressed by neurons and their activation is primarily implicated in psychotropic and motor effects of cannabinoids. CB2 receptors are expressed by glial cells and are thought to participate in regulation of neuroimmune reactions. This review aims to highlight several reported properties of cannabinoids that could be used to inhibit the adverse neuroinflammatory processes contributing to Parkinson's disease and possibly other neurodegenerative disorders. These include anti-oxidant properties of phytocannabinoids and synthetic cannabinoids as well as hypothermic and antipyretic effects. However, cannabinoids may also trigger signaling cascades leading to impaired mitochondrial enzyme activity, reduced mitochondrial biogenesis, and increased oxidative stress, all of which could contribute to neurotoxicity. Therefore, further pharmacological studies are needed to allow rational design of new cannabinoid-based drugs lacking detrimental in vivo effects.
KW - Animals
KW - Antioxidants/pharmacology
KW - Cannabinoids/pharmacology
KW - Humans
KW - Inflammation/drug therapy
KW - Microglia/cytology
KW - Parkinson Disease/drug therapy
KW - Psychotropic Drugs/pharmacology
U2 - 10.2174/138955711795906905
DO - 10.2174/138955711795906905
M3 - Review
C2 - 21699489
VL - 11
SP - 582
EP - 590
JO - Mini-Reviews in Medicinal Chemistry
JF - Mini-Reviews in Medicinal Chemistry
SN - 1389-5575
IS - 7
ER -
ID: 236611767